Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896033 · ClinicalTrials.gov registry record · NA
Impact of Cigarette and E-cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes
A NA study of Smoking Prevention and Control, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT05896033: Recruiting NA study of Smoking Prevention and Control, sponsored by Medical University of South Carolina.
NCT05896033 is a NA study of Smoking Prevention and Control that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 240 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05896033, a NA study of Smoking Prevention and Control, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
In a 2x2 design, current menthol smokers (N=240) will complete a baseline period before being assigned to a cigarette (menthol or non-menthol) and e-cigarette condition (menthol or tobacco-flavored e-liquid) and receiving a 7-week supply of cigarettes and e-cigarettes. The study builds upon our well-established methodology for simulating tobacco regulatory policies. To model a ban, smokers will be instructed to only use their assigned products. Primary outcomes include cigarette smoking and e-cigarette use during Week 6. However, because a menthol ban may impact the ability to abstain from smoking, the investigators will incentivize participants to abstain from smoking during Week 7 (continued e-cigarette use allowed) and assess the time to first lapse. Participants will complete daily electronic diaries assessing tobacco product use throughout, which will be corroborated by biomarkers for menthol, nicotine, and smoke. Finally, to maximize the utility of these data for FDA regulation, the investigators will assess whether any demographic or baseline smoking characteristics moderate the observed treatment effects, calibrate the treatment effects to the US adult menthol smoking population, and model the effects of menthol regulation in cigarettes and e-cigarettes on smoking and vaping-attributable deaths and life-years lost.
Primary Outcome
Will be measured through week 6 of the study
Conditions Studied
Interventions
- BEHAVIORAL Non-Menthol Cigarettes
- BEHAVIORAL Tobacco Flavored E-cigarettes
- BEHAVIORAL Menthol Cigarettes
- BEHAVIORAL Menthol Flavored E-cigarettes
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT05896033 shows while recruiting
NCT05896033 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Smoking Prevention and Control appearing as the primary indexed condition, and to 4 interventions - of which Non-Menthol Cigarettes is the first listed.
NCT05896033 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT05896033 about?
NCT05896033 is a clinical study titled "Impact of Cigarette and E-cigarette Menthol Regulation on Current Smokers of Menthol Cigarettes". In a 2x2 design, current menthol smokers (N=240) will complete a baseline period before being assigned to a cigarette (menthol or non-menthol) and e-cigarette condition (menthol or tobacco-flavored e-liquid) and receiving a 7-week supply of cigarettes and e-cigarettes. The study builds upon our well...
What is the current status of trial NCT05896033?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2023-10-23. Estimated completion is 2027-08-31.
What conditions does trial NCT05896033 study?
This clinical trial studies the following conditions: Smoking Prevention and Control.
What interventions are being tested in trial NCT05896033?
The interventions under investigation include: Non-Menthol Cigarettes (BEHAVIORAL), Tobacco Flavored E-cigarettes (BEHAVIORAL), Menthol Cigarettes (BEHAVIORAL), Menthol Flavored E-cigarettes (BEHAVIORAL).
Who is sponsoring clinical trial NCT05896033?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05896033 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05896033's enrollment target sits among peer trials
240 440th of 2000 higher than 1,543 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI